• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The SHIFT: Ivabradine in congestive heart failure [Classics Series]

byMichael MilliganandAndrew Cheung, MD MBA
June 20, 2017
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with congestive heart failure (CHF) and baseline heart rate >70 bpm, ivabradine significantly reduced the risk of heart failure hospitalization and death from heart failure compared to placebo.

2. Compared to those on placebo, patients taking ivabradine experienced significantly higher rates of atrial fibrillation, asymptomatic and symptomatic bradycardia.

Original Date of Publication: August 2010

Study Rundown: CHF is a common condition across much of the developed world and is a significant source of morbidity and mortality. Current therapies for CHF, including angiotensin-converting-enzyme (ACE) inhibitors and β-blockers, work in part by reducing cardiac workload and harmful remodeling. However, even with maximally tolerated doses of β-blockers, many patients still present with elevated heart rates, a factor linked to increased rates of hospitalization and cardiovascular death. Ivabradine, a novel inhibitor of the “funny current” (If) channels, was found to selectively reduce heart rate in preclinical studies. The Systolic Heart failure with the If inhibitor ivabradine Trial (SHIFT) sought to investigate the effect of ivabradine on patients with CHF.

This multinational, randomized controlled trial compared adding ivabradine or placebo to standard therapy in patients with CHF and a baseline heart rate >70 bpm. In summary, patients receiving ivabradine achieved significant reductions in their average resting heart rate and experienced lower rates of cardiovascular death and hospitalization for CHF than those taking placebo. This study is limited in its generalizability, as patients with arrhythmias and severe CHF were excluded. Nevertheless, the results do suggest that heart rate plays a significant role in the progression of heart failure, and that the introduction of ivabradine may improve outcomes.

Click to read the study in The Lancet

In-Depth [randomized controlled trial]: This multinational, double-blind, randomized controlled trial was conducted in 677 institutions in 37 countries. A total of 6558 adults with stable symptomatic heart failure, a prior hospitalization for CHF, an ejection fraction <35%, and a resting heart rate >70 bpm were enrolled in the study. These participants were all maintained on standard medical therapy and randomly assigned to receive placebo or a twice-daily dose of ivabradine titrated to achieve a heart rate between 50 and 60 bpm. Exclusion criteria included recent myocardial infarction in the preceeding 2 months, ventricular or atrioventricular pacing for >40% of the day, atrial fibrillation or flutter, and symptomatic hypotension. Patients were followed for a median of 22.9 months. The primary outcome was a composite endpoint of cardiovascular death or hospitalization for worsening CHF.

RELATED REPORTS

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

Compared to the placebo group, heart rates in patients taking ivabradine were reduced by 10.9 bpm (95%CI 10.4-11.4 bpm). Patients in the ivabradine group experienced significantly lower rates of the primary outcome compared to those on placebo (HR 0.82, 95%CI 0.75-0.90, p < 0.0001). The effect was driven mainly by reduced rates of hospitalization (HR 0.74; 95%CI 0.66-0.83, p < 0.0001) and lower mortality from heart failure (HR 0.74, 95%CI 0.58-0.94, p = 0.014, respectively). In total, there were fewer adverse events reported in the ivabradine group than in the placebo group, although ivabradine was associated with increased rates of atrial fibrillation (p = 0.012), asymptomatic bradycardia (p < 0.0001), symptomatic bradycardia (p < 0.0001), and visual disturbances (p < 0.0001).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congestive heart failureshift
Previous Post

Study reveals suburban clinicians’ perspectives on screening for food insecurity

Next Post

The FREEDOM trial: Coronary bypass graft vs. PCI in diabetic patients [Classics Series]

RelatedReports

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
StudyGraphics

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

January 27, 2023
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

November 8, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Hemodynamic-guided management of heart failure may reduce hospitalization rates

September 22, 2021
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The FREEDOM trial: Coronary bypass graft vs. PCI in diabetic patients [Classics Series]

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

2 Minute Medicine Rewind June 19, 2017

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The AREDS1: Zinc and antioxidant supplementation reduce progression of AMD in high-risk patients [The Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options